Fatal insomnia is a rare genetic brain disorder that affects less than 40 families globally. The average age of onset of symptoms is 50 years, and the disease is equally likely to affect both genders.

The disease is progressive, and patients eventually lose the ability to sleep, ultimately resulting in death. The condition’s prognosis is grim, as it is fatal within a few months to a few years.

Symptoms of Fatal Insomnia

Fatal insomnia is characterized by a number of symptoms. The initial symptoms, which are typically not recognizable as related to a serious disease, include difficulties falling asleep, which can result in fatigue and anxiety.

With progression, the symptoms become more severe, and patients may experience confusion, hallucinations, and paranoia. The confusion often results in an inability to recognize familiar people or places. As the disease progresses, patients develop rapidly progressive dementia, which eventually leads to complete insomnia.

The patient’s ability to control basic physical actions also deteriorates with time and may lead to urinary and fecal incontinence.

Causes of Fatal Insomnia

Fatal insomnia is caused by the formation of a prion protein that destroys specific areas of the brain. This process is called neurodegeneration.

The prion protein that causes fatal insomnia results from a muattion in the prion protein gene (PRNP), on chromosome 20. The mutation leads to the buildup of misfolded prion proteins in the brain. These proteins are resistant to the normal degradation and accumulate to damage brain tissue, which leads to the symptoms of the fatal disease.

Diagnosis of Fatal Insomnia

The diagnosis of fatal insomnia is challenging given the rarity of the disease and the need for a genetic test.

It is diagnosed based on clinical symptoms and a genetic test, which identifies a mutation in the PRNP gene, present in affected family members. A comprehensive neurological and psychological examination is done to evaluate the extent of the symptoms and the progression of the disease. Polysomnography or a sleep study may be performed to evaluate sleep-wake cycles.

Treatment of Fatal Insomnia

Currently, there is no treatment for fatal insomnia, and the course of the disease is progressive and fatal. Symptomatic treatment may be provided to ease the symptoms, such as anxiety, depression, and hallucinations.

Related Article Deadly Insomnia: The Silent Killer

The patient’s family may require psychological counseling to help in coping with the patient’s deteriorating condition.

Prevalence of Fatal Insomnia

Fatal insomnia is exceptionally rare. Less than 40 families worldwide have been reported with the disease.

Multiple families from various ethnic groups, geographical regions, and races are reported with the disease, indicating that this is a widespread genetic defect.

Genetic Testing for Fatal Insomnia

Genetic testing is the gold standard for the diagnosis of fatal insomnia. The most common mutation is located in the PRNP gene, located on chromosome 20.

Genetic testing can help identify family members who have the mutation, which is necessary for early diagnosis and intervention, psychological counseling, and family planning.

Research on Fatal Insomnia

There is limited research on fatal insomnia due to the rarity of the disease. Discovery of a mutation in the PRNP gene allowed for early detection and ensured better genealogical tracing.

The most recent studies have been mainly devoted to the search for a genotype-phenotype correlations, as well as to the development of potential treatments. Gene therapy may hold the most promising approach to help in preventing the development of the disease in affected patients.

Conclusion

Fatal Insomnia is a rare and fatal genetic brain disorder characterized by an inability to sleep. The course of the disease is progressive, and its prognosis is uniformly fatal. The current treatments are symptomatic, with no cure for the disease.

Genetic testing is necessary for early intervention. Ongoing studies on the disease are required to understand the underlying mechanisms, characterize the symptoms better, and develop promising genetic therapy to prevent the development of the disease.